Smith & Nephew Buys Healthpoint Biotherapeutics for $782M
The targets products which include Oasis Wound Matrix, Xenaderm Ointment, Prudoxin and Curasol focus on burn care.
Smith & Nephew plc (NYSE: SNN) will acquire Healthpoint Biotherapeutics’ assets for $782 million in cash.
Fort Worth, Texas-based Healthpoint focuses on biopharmaceutical products related to burn wound care. Its portfolio of products include Oasis Wound Matrix, Xenaderm Ointment, Prudoxin and Curasol.
Smith & Nephew, headquartered in London, is a medical technology business that offers products for orthopedic reconstruction, trauma, sports medicine and advanced wound management.
For more information on related topics, visit the following: